Moreover, an ongoing clinical trial evaluating the efficacy of combining MET and EGFR TKIs in EGFR-mutated NSCLC patients with MET-driven resistance to EGFR TKIs includes patients with both MET amplification or MET overexpression (NCT01610336). This evidence concerns the gene MET and non-small cell lung carcinoma.